Summit Therapeutics PLC Sponsored ADR Stock

$18.21

5.55% day before yesterday

Nasdaq, Dec 27, 10:08 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$18.21

+16.66 1,074.84% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-1.07 5.55%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$13.42b
Enterprise Value	$12.97b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	30.65
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-181.89m
Free Cash Flow (TTM) Free Cash Flow	$-113.54m
Cash position	$487.22m
EPS (TTM) EPS	$-0.28
P/E forward	negative
Short interest	14.17%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

5x Buy

83%

1x Hold

17%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

83%

Hold

17%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.67 0.67	67% 67% -
Gross Profit	-0.67 -0.67	67% 67% -
- Selling and Administrative Expenses	56 56	152% 152% -
- Research and Development Expense	124 124	212% 212% -
EBITDA	-181 -181	182% 182% -
- Depreciation and Amortization	0.67 0.67	67% 67% -
EBIT (Operating Income) EBIT	-182 -182	174% 174% -
Net Profit	-197 -197	67% 67% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

9 days ago

Where Will Summit Therapeutics Be in 5 Years?

Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023.

Positive

The Motley Fool

●

9 days ago

3 Stocks That Could Turn $1,000 into $5,000 by 2030

A five-bagger in only five years? Any investor would love to buy such a stock.

Neutral

The Motley Fool

●

11 days ago

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	105
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now